The Cerebral Spinal Fluid Management Market valued for $675.44 million in 2021 and is estimated to reach $1,032.56 million by 2031, exhibiting a CAGR of 4.4% from 2022 to 2031.
Hydrocephalus refers to the buildup of fluid in the ventricles deep within the brain. The excess fluid called cerebral spinal fluid increases the size of the ventricles and puts pressure on the brain. It can be treated with the use of cerebral spinal fluid management devices. Cerebrospinal fluid (CSF) management devices involve the devices such as shunts and external drainage systems to maintain the flow of CSF and drain excess fluid from the brain. Increased intracranial pressure can result in irreversible injury to the central nervous system. It provides protection against acute changes in venous and arterial blood pressure or impact pressure. Nevertheless, trauma, tumors, infections, neurosurgical procedures, and other factors can cause increased intracranial pressure. Both surgical and nonsurgical therapeutic modalities can be used in the management of increased intracranial pressure attributable to traumatic and non-traumatic causes. In patients with cerebral injury and increased intracranial pressure, monitoring of the intracranial pressure can provide an objective measure of the response to therapy and the pressure dynamics. Intraventricular, intraparenchymal, subarachnoid, and epidural sites can be used for monitoring, and the advantages and disadvantages of the various devices available.
The growth of the cerebral spinal fluid management market is driven by increase in the number of brain surgeries, surge in number of research and development activities, rise in expenditure on the product development by the government & private organizations and increase in the technological advancements of the cerebral spinal fluid management devices and increase in the number of research laboratories. Moreover, the disruption of normal cerebral spinal fluid circulation and turnover is believed to contribute to the development of many neurodegenerative conditions such as Alzheimer's disease, ischemic and traumatic brain injury, and neuroinflammatory conditions such as multiple sclerosis. Hence, increase in the adoption of cerebral spinal fluid management devices boosts the growth of the market. In addition, increase in the research pipeline among the pharmaceutical and biotechnology research organizations and surge in awareness about research studies on the conditions of disrupted volume of cerebral spinal fluid foster the growth of the market. For instance, according to the study of National Library of Medicine, in June 2021, there were 687 neurosurgery admissions in India during the study period compared with 2550 admissions in 2019. The total number of surgeries performed in neurosurgery also showed a similar trend, with only 654 surgeries in 2020 compared with 3165 surgeries in 2019. Moreover, increase in the geriatric population which are more prone to the neurological disorders are also contributing in the demand of the market. However, the high cost of the treatment for cerebral spinal fluid related diseases is expected to hinder the growth of the market.
The cerebral spinal fluid management market is segmented on the basis of type, age group and region. On the basis of type, the market is bifurcated into CSF shunts and external drainage system. On the basis of age group, the market is classified into pediatric and adult. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major companies profiled in the report include B. Braun Melsungen AG, Delta Surgical, G. SURGIWEAR LTD, Integra Lifesciences Holdings, Medtronic plc, Moller Medical GMBH, Natus Medical Incorporated, Spiegelberg GmbH & Co. KG, Tokibo Co., Ltd., and Wellong Pharma.
Hydrocephalus refers to the buildup of fluid in the ventricles deep within the brain. The excess fluid called cerebral spinal fluid increases the size of the ventricles and puts pressure on the brain. It can be treated with the use of cerebral spinal fluid management devices. Cerebrospinal fluid (CSF) management devices involve the devices such as shunts and external drainage systems to maintain the flow of CSF and drain excess fluid from the brain. Increased intracranial pressure can result in irreversible injury to the central nervous system. It provides protection against acute changes in venous and arterial blood pressure or impact pressure. Nevertheless, trauma, tumors, infections, neurosurgical procedures, and other factors can cause increased intracranial pressure. Both surgical and nonsurgical therapeutic modalities can be used in the management of increased intracranial pressure attributable to traumatic and non-traumatic causes. In patients with cerebral injury and increased intracranial pressure, monitoring of the intracranial pressure can provide an objective measure of the response to therapy and the pressure dynamics. Intraventricular, intraparenchymal, subarachnoid, and epidural sites can be used for monitoring, and the advantages and disadvantages of the various devices available.
The growth of the cerebral spinal fluid management market is driven by increase in the number of brain surgeries, surge in number of research and development activities, rise in expenditure on the product development by the government & private organizations and increase in the technological advancements of the cerebral spinal fluid management devices and increase in the number of research laboratories. Moreover, the disruption of normal cerebral spinal fluid circulation and turnover is believed to contribute to the development of many neurodegenerative conditions such as Alzheimer's disease, ischemic and traumatic brain injury, and neuroinflammatory conditions such as multiple sclerosis. Hence, increase in the adoption of cerebral spinal fluid management devices boosts the growth of the market. In addition, increase in the research pipeline among the pharmaceutical and biotechnology research organizations and surge in awareness about research studies on the conditions of disrupted volume of cerebral spinal fluid foster the growth of the market. For instance, according to the study of National Library of Medicine, in June 2021, there were 687 neurosurgery admissions in India during the study period compared with 2550 admissions in 2019. The total number of surgeries performed in neurosurgery also showed a similar trend, with only 654 surgeries in 2020 compared with 3165 surgeries in 2019. Moreover, increase in the geriatric population which are more prone to the neurological disorders are also contributing in the demand of the market. However, the high cost of the treatment for cerebral spinal fluid related diseases is expected to hinder the growth of the market.
The cerebral spinal fluid management market is segmented on the basis of type, age group and region. On the basis of type, the market is bifurcated into CSF shunts and external drainage system. On the basis of age group, the market is classified into pediatric and adult. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major companies profiled in the report include B. Braun Melsungen AG, Delta Surgical, G. SURGIWEAR LTD, Integra Lifesciences Holdings, Medtronic plc, Moller Medical GMBH, Natus Medical Incorporated, Spiegelberg GmbH & Co. KG, Tokibo Co., Ltd., and Wellong Pharma.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cerebral spinal fluid management market analysis from 2021 to 2031 to identify the prevailing cerebral spinal fluid management market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the cerebral spinal fluid management market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global cerebral spinal fluid management market trends, key players, market segments, application areas, and market growth Strategies.
Key Market Segments
By Type
- CSF shunts
- External drainage system
By Age group
- Pediatric
- Adult
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- B. Braun Melsungen AG
- Delta Surgical
- Spiegelberg GmbH & Co. KG
- Möller Medical GmbH
- Tokibo Co.,Ltd
- Medtronic plc
- G. Surgiwear Ltd.
- Integra LifeSciences Holdings
- Wellona Pharma
- Natus Medical Incorporated
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in the prevalence of brain disorders
3.4.1.2. Increase in the geriatric population
3.4.1.3. Rise in demand for development in the CSF shunts
3.4.2. Restraints
3.4.2.1. Complications related to the shunts
3.4.3. Opportunities
3.4.3.1. Rise in the of research and developments (R&D) activities
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. CSF shunts
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. External drainage system
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP
5.1. Overview
5.1.1. Market size and forecast
5.2. Pediatric
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Adult
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: CEREBROSPINAL FLUID MANAGEMENT MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key trends and opportunities
6.2.2. Market size and forecast, by Type
6.2.3. Market size and forecast, by Age group
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Key market trends, growth factors and opportunities
6.2.4.1.2. Market size and forecast, by Type
6.2.4.1.3. Market size and forecast, by Age group
6.2.4.2. Canada
6.2.4.2.1. Key market trends, growth factors and opportunities
6.2.4.2.2. Market size and forecast, by Type
6.2.4.2.3. Market size and forecast, by Age group
6.2.4.3. Mexico
6.2.4.3.1. Key market trends, growth factors and opportunities
6.2.4.3.2. Market size and forecast, by Type
6.2.4.3.3. Market size and forecast, by Age group
6.3. Europe
6.3.1. Key trends and opportunities
6.3.2. Market size and forecast, by Type
6.3.3. Market size and forecast, by Age group
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Key market trends, growth factors and opportunities
6.3.4.1.2. Market size and forecast, by Type
6.3.4.1.3. Market size and forecast, by Age group
6.3.4.2. France
6.3.4.2.1. Key market trends, growth factors and opportunities
6.3.4.2.2. Market size and forecast, by Type
6.3.4.2.3. Market size and forecast, by Age group
6.3.4.3. UK
6.3.4.3.1. Key market trends, growth factors and opportunities
6.3.4.3.2. Market size and forecast, by Type
6.3.4.3.3. Market size and forecast, by Age group
6.3.4.4. Italy
6.3.4.4.1. Key market trends, growth factors and opportunities
6.3.4.4.2. Market size and forecast, by Type
6.3.4.4.3. Market size and forecast, by Age group
6.3.4.5. Spain
6.3.4.5.1. Key market trends, growth factors and opportunities
6.3.4.5.2. Market size and forecast, by Type
6.3.4.5.3. Market size and forecast, by Age group
6.3.4.6. Rest of Europe
6.3.4.6.1. Key market trends, growth factors and opportunities
6.3.4.6.2. Market size and forecast, by Type
6.3.4.6.3. Market size and forecast, by Age group
6.4. Asia-Pacific
6.4.1. Key trends and opportunities
6.4.2. Market size and forecast, by Type
6.4.3. Market size and forecast, by Age group
6.4.4. Market size and forecast, by country
6.4.4.1. China
6.4.4.1.1. Key market trends, growth factors and opportunities
6.4.4.1.2. Market size and forecast, by Type
6.4.4.1.3. Market size and forecast, by Age group
6.4.4.2. Japan
6.4.4.2.1. Key market trends, growth factors and opportunities
6.4.4.2.2. Market size and forecast, by Type
6.4.4.2.3. Market size and forecast, by Age group
6.4.4.3. India
6.4.4.3.1. Key market trends, growth factors and opportunities
6.4.4.3.2. Market size and forecast, by Type
6.4.4.3.3. Market size and forecast, by Age group
6.4.4.4. Australia
6.4.4.4.1. Key market trends, growth factors and opportunities
6.4.4.4.2. Market size and forecast, by Type
6.4.4.4.3. Market size and forecast, by Age group
6.4.4.5. South Korea
6.4.4.5.1. Key market trends, growth factors and opportunities
6.4.4.5.2. Market size and forecast, by Type
6.4.4.5.3. Market size and forecast, by Age group
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Key market trends, growth factors and opportunities
6.4.4.6.2. Market size and forecast, by Type
6.4.4.6.3. Market size and forecast, by Age group
6.5. LAMEA
6.5.1. Key trends and opportunities
6.5.2. Market size and forecast, by Type
6.5.3. Market size and forecast, by Age group
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Key market trends, growth factors and opportunities
6.5.4.1.2. Market size and forecast, by Type
6.5.4.1.3. Market size and forecast, by Age group
6.5.4.2. Saudi Arabia
6.5.4.2.1. Key market trends, growth factors and opportunities
6.5.4.2.2. Market size and forecast, by Type
6.5.4.2.3. Market size and forecast, by Age group
6.5.4.3. South Africa
6.5.4.3.1. Key market trends, growth factors and opportunities
6.5.4.3.2. Market size and forecast, by Type
6.5.4.3.3. Market size and forecast, by Age group
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Key market trends, growth factors and opportunities
6.5.4.4.2. Market size and forecast, by Type
6.5.4.4.3. Market size and forecast, by Age group
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning Strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2021
CHAPTER 8: COMPANY PROFILES
8.1. Medtronic plc
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.2. B. Braun Melsungen AG
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.3. Integra LifeSciences Holdings
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.4. Wellona Pharma
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.5. Delta Surgical
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.6. Spiegelberg GmbH & Co. KG
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.7. G. Surgiwear Ltd.
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.8. Möller Medical GmbH
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.9. Natus Medical Incorporated
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.10. Tokibo Co.,Ltd
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
List of Tables
Table 01. Global Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 02. Cerebrospinal Fluid Management Market for Csf Shunts, by Region, 2021-2031 (Revenue, $Million)
Table 03. Cerebrospinal Fluid Management Market for External Drainage System, by Region, 2021-2031 (Revenue, $Million)
Table 04. Global Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 05. Cerebrospinal Fluid Management Market for Pediatric, by Region, 2021-2031 (Revenue, $Million)
Table 06. Cerebrospinal Fluid Management Market for Adult, by Region, 2021-2031 (Revenue, $Million)
Table 07. Cerebrospinal Fluid Management Market, by Region, 2021-2031 (Revenue, $Million)
Table 08. North America Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 09. North America Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 10. North America Cerebrospinal Fluid Management Market, by Country, 2021-2031 (Revenue, $Million)
Table 11. U.S. Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 12. U.S. Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 13. Canada Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 14. Canada Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 15. Mexico Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 16. Mexico Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 17. Europe Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 18. Europe Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 19. Europe Cerebrospinal Fluid Management Market, by Country, 2021-2031 (Revenue, $Million)
Table 20. Germany Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 21. Germany Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 22. France Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 23. France Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 24. UK Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 25. UK Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 26. Italy Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 27. Italy Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 28. Spain Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 29. Spain Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 30. Rest of Europe Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 31. Rest of Europe Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 32. Asia-Pacific Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 33. Asia-Pacific Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 34. Asia-Pacific Cerebrospinal Fluid Management Market, by Country, 2021-2031 (Revenue, $Million)
Table 35. China Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 36. China Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 37. Japan Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 38. Japan Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 39. India Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 40. India Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 41. Australia Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 42. Australia Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 43. South Korea Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 44. South Korea Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 45. Rest of Asia-Pacific Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 46. Rest of Asia-Pacific Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 47. LAMEA Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 48. LAMEA Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 49. LAMEA Cerebrospinal Fluid Management Market, by Country, 2021-2031 (Revenue, $Million)
Table 50. Brazil Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 51. Brazil Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 52. Saudi Arabia Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 53. Saudi Arabia Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 54. South Africa Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 55. South Africa Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 56. Rest of LAMEA Cerebrospinal Fluid Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 57. Rest of LAMEA Cerebrospinal Fluid Management Market, by Age Group, 2021-2031 (Revenue, $Million)
Table 58. Medtronic PLC: Key Executives
Table 59. Medtronic PLC: Company Snapshot
Table 60. Medtronic PLC: Product Segments
Table 61. Medtronic PLC: Product Portfolio
Table 62. B. Braun Melsungen AG: Key Executives
Table 63. B. Braun Melsungen AG: Company Snapshot
Table 64. B. Braun Melsungen AG: Product Segments
Table 65. B. Braun Melsungen AG: Product Portfolio
Table 66. Integra Lifesciences Holdings: Key Executives
Table 67. Integra Lifesciences Holdings: Company Snapshot
Table 68. Integra Lifesciences Holdings: Product Segments
Table 69. Integra Lifesciences Holdings: Product Portfolio
Table 70. Wellona Pharma: Key Executives
Table 71. Wellona Pharma: Company Snapshot
Table 72. Wellona Pharma: Product Segments
Table 73. Wellona Pharma: Product Portfolio
Table 74. Delta Surgical: Key Executives
Table 75. Delta Surgical: Company Snapshot
Table 76. Delta Surgical: Product Segments
Table 77. Delta Surgical: Product Portfolio
Table 78. Spiegelberg GmbH & Co. KG: Key Executives
Table 79. Spiegelberg GmbH & Co. KG: Company Snapshot
Table 80. Spiegelberg GmbH & Co. KG: Product Segments
Table 81. Spiegelberg GmbH & Co. KG: Product Portfolio
Table 82. G. Surgiwear Ltd.: Key Executives
Table 83. G. Surgiwear Ltd.: Company Snapshot
Table 84. G. Surgiwear Ltd.: Product Segments
Table 85. G. Surgiwear Ltd.: Product Portfolio
Table 86. Möller Medical GmbH: Key Executives
Table 87. Möller Medical GmbH: Company Snapshot
Table 88. Möller Medical GmbH: Product Segments
Table 89. Möller Medical GmbH: Product Portfolio
Table 90. Natus Medical Incorporated: Key Executives
Table 91. Natus Medical Incorporated: Company Snapshot
Table 92. Natus Medical Incorporated: Product Segments
Table 93. Natus Medical Incorporated: Product Portfolio
Table 94. Tokibo Co.,Ltd.: Key Executives
Table 95. Tokibo Co.,Ltd.: Company Snapshot
Table 96. Tokibo Co.,Ltd.: Product Segments
Table 97. Tokibo Co.,Ltd.: Product Portfolio
List of Figures
Figure 01. Cerebrospinal Fluid Management Market, 2021-2031
Figure 02. Segmentation of Cerebrospinal Fluid Management Market, 2021-2031
Figure 03. Top Investment Pockets in Cerebrospinal Fluid Management Market (2022-2031)
Figure 04. Moderate Bargaining Power of Suppliers
Figure 05. Moderate Bargaining Power of Buyers
Figure 06. Moderate Threat of Substitutes
Figure 07. Moderate Threat of New Entrants
Figure 08. Moderate Intensity of Rivalry
Figure 09. Drivers, Restraints and Opportunities: Globalcerebrospinal Fluid Management Market
Figure 10. Cerebrospinal Fluid Management Market, by Type, 2021(%)
Figure 11. Comparative Share Analysis of Cerebrospinal Fluid Management Market for Csf Shunts, by Country 2021-2031(%)
Figure 12. Comparative Share Analysis of Cerebrospinal Fluid Management Market for External Drainage System, by Country 2021-2031(%)
Figure 13. Cerebrospinal Fluid Management Market, by Age Group, 2021(%)
Figure 14. Comparative Share Analysis of Cerebrospinal Fluid Management Market for Pediatric, by Country 2021-2031(%)
Figure 15. Comparative Share Analysis of Cerebrospinal Fluid Management Market for Adult, by Country 2021-2031(%)
Figure 16. Cerebrospinal Fluid Management Market by Region, 2021
Figure 17. U.S. Cerebrospinal Fluid Management Market, 2021-2031 ($Million)
Figure 18. Canada Cerebrospinal Fluid Management Market, 2021-2031 ($Million)
Figure 19. Mexico Cerebrospinal Fluid Management Market, 2021-2031 ($Million)
Figure 20. Germany Cerebrospinal Fluid Management Market, 2021-2031 ($Million)
Figure 21. France Cerebrospinal Fluid Management Market, 2021-2031 ($Million)
Figure 22. UK Cerebrospinal Fluid Management Market, 2021-2031 ($Million)
Figure 23. Italy Cerebrospinal Fluid Management Market, 2021-2031 ($Million)
Figure 24. Spain Cerebrospinal Fluid Management Market, 2021-2031 ($Million)
Figure 25. Rest of Europe Cerebrospinal Fluid Management Market, 2021-2031 ($Million)
Figure 26. China Cerebrospinal Fluid Management Market, 2021-2031 ($Million)
Figure 27. Japan Cerebrospinal Fluid Management Market, 2021-2031 ($Million)
Figure 28. India Cerebrospinal Fluid Management Market, 2021-2031 ($Million)
Figure 29. Australia Cerebrospinal Fluid Management Market, 2021-2031 ($Million)
Figure 30. South Korea Cerebrospinal Fluid Management Market, 2021-2031 ($Million)
Figure 31. Rest of Asia-Pacific Cerebrospinal Fluid Management Market, 2021-2031 ($Million)
Figure 32. Brazil Cerebrospinal Fluid Management Market, 2021-2031 ($Million)
Figure 33. Saudi Arabia Cerebrospinal Fluid Management Market, 2021-2031 ($Million)
Figure 34. South Africa Cerebrospinal Fluid Management Market, 2021-2031 ($Million)
Figure 35. Rest of LAMEA Cerebrospinal Fluid Management Market, 2021-2031 ($Million)
Figure 36. Top Winning Strategies, by Year
Figure 37. Top Winning Strategies, by Development
Figure 38. Top Winning Strategies, by Company
Figure 39. Product Mapping of Top 10 Players
Figure 40. Competitive Dashboard
Figure 41. Competitive Heatmap: Cerebrospinal Fluid Management Market
Figure 42. Top Player Positioning, 2021
Figure 43. Medtronic PLC: Net Sales, 2020-2022 ($Million)
Figure 44. Medtronic PLC: Revenue Share by Segment, 2022 (%)
Figure 45. Medtronic PLC: Revenue Share by Region, 2022 (%)
Figure 46. B. Braun Melsungen AG: Net Sales, 2019-2021 ($Million)
Figure 47. B. Braun Melsungen AG: Revenue Share by Region, 2021 (%)
Figure 48. B. Braun Melsungen AG: Revenue Share by Segment, 2021 (%)
Figure 49. Integra Lifesciences Holdings: Net Revenue, 2019-2021 ($Million)
Figure 50. Integra Lifesciences Holdings: Research & Development Expenditure, 2019-2021
Figure 51. Integra Lifesciences Holdings: Revenue Share by Region, 2021 (%)
Figure 52. Integra Lifesciences Holdings: Revenue Share by Segment, 2021 (%)
Figure 53. Natus Medical Incorporated: Net Revenue, 2019-2021 ($Million)
Figure 54. Natus Medical Incorporated: Revenue Share by Segment, 2021 (%)
Figure 55. Natus Medical Incorporated: Revenue Share by Region, 2021 (%)
Executive Summary
According to the report titled, 'Cerebral Spinal Fluid Management Market,' the cerebral spinal fluid management market was valued at $0.67 billion in 2021, and is estimated to reach $1.03 billion by 2031, growing at a CAGR of 4.4% from 2022 to 2031.The Cerebral Spinal Fluid Management Market is likely to experience a significant growth rate of 4.4% from 2022-2031 owing to increasing market demand from medical device sector.
Cerebrospinal fluid (CSF) is an ultrafiltrate of plasma contained within the ventricles of the brain. The placement of devices like cerebral spinal fluid (CSF) shunt systems to treat hydrocephalus is a common medical procedure and a life-saving treatment for many patients that are in need of cerebral spinal fluid management. The shunt systems drain excess fluid from the brain to another part of the body where the fluid is absorbed as part of the circulatory process.
Cerebrospinal fluid (CSF) is an ultrafiltrate of plasma contained within the ventricles of the brain. The placement of devices like cerebral spinal fluid (CSF) shunt systems to treat hydrocephalus is a common medical procedure and a life-saving treatment for many patients that are in need of cerebral spinal fluid management. The shunt systems drain excess fluid from the brain to another part of the body where the fluid is absorbed as part of the circulatory process.
Key factors driving the growth of the cerebral spinal fluid management market include increase in prevalence of brain disorders, rise in the expenditure on the product development by the government & private organizations and increase in the technological advancements of the cerebral spinal fluid management devices and increase in the number of research laboratories. For instance, according to a data by report published in the National Center for Biotechnology Information in 2021, a part of the U.S. National Library of Medicine, a branch of the National Institutes of Health, the global prevalence of hydrocephalus was reported around 85 per 100,000 people, with a notable disparity between age groups, 88 per 100,000 in children and 11 per 100,000 in adults. Moreover, injuries such as intraventricular hemorrhage, stroke, tumor, and several other types of CSF infections can result in the development of hydrocephalic conditions among patients thereby boosting the growth of market. However, increase in costs of the devices is expected to hinder the growth of the market.
The market also offers growth opportunities to the key players in the market. The target population is in tremendous need of the devices in the region like Europe and Asia-Pacific. Hence, challenges to cater the unmet needs of the target population provides the growth opportunities. The online device delivery services have gained high traction in the last 4 years. As a result, engaged stakeholders in the industry have partnered with existing delivery services organization.
The global cerebral spinal fluid management market is segmented based on the basis of type, age group and region. On the basis of type, the market is bifurcated into CSF shunts and external drainage system. On the basis of age group, the market is classified into pediatric and adult. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include B. Braun Melsungen AG, Delta Surgical, G. SURGIWEAR LTD, Integra Lifesciences Holdings, Medtronic plc, Moller Medical GMBH, Natus Medical Incorporated, Spiegelberg GmbH & Co. KG, Tokibo Co., Ltd., and Wellong Pharma. The players in the market have been actively engaged in the adoption various Strategies such as product approval, product launch, and partnership to remain competitive and gain advantage over the competitors in the market. For instance, in May 2022, Aesculap, Inc., a Germany-based manufacturer of surgical instruments, medical devices and sterilization container systems, announced a partnership with the Christoph Miethke GmbH & Co. KG. The partnership aimed at launching the latest generation of Hydrocephalus valve technology, M.blue valve. Its distinctive gravitational technology combined with a fixed differential pressure unit in a single valve to provide a straightforward, position-dependent solution.
Key Market Insights
By type, the CSF shunts segment is the highest revenue contributor to the market and is estimated to continue this during the analysis period, with a CAGR of 4.3%. However, the external drainage system segment is estimated to be the fastest-growing segment with a CAGR of 4.7% during the forecast period.Based on age group, the adult segment was the highest revenue contributor to the market with a CAGR of 4.2% during the forecast period. However, the pediatric segment is estimated to be the fastest-growing segment with a CAGR of 4.6% during the forecast period.
Based on region, North America garnered the largest revenue share in 2021. However, the Asia-Pacific is estimated to be the fastest-growing segment with a CAGR of 5.6% during the forecast period.
Companies Mentioned
- B. Braun Melsungen AG
- Delta Surgical
- Spiegelberg GmbH & Co. KG
- Möller Medical GmbH
- Tokibo Co.,Ltd
- Medtronic plc
- G. Surgiwear Ltd.
- Integra LifeSciences Holdings
- Wellona Pharma
- Natus Medical Incorporated
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
